Analysis of p53 expression and proliferative assessment using PCNA in localized prostate carcinoma

Brazilian Journal of Medical and Biological Research

Volumn 32, Issue 3, 1999, Pages 283-288

  Leite, K R M ^a,c   Srougi, M ^b   Nesralhah, L J ^b   Camara Lopes, L H ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

p53; PCNA; Proliferating cell nuclear antigen; Prostate carcinoma

Indexed keywords

CYCLINE;

AGED; ARTICLE; CANCER STAGING; CARCINOMA; CELL DIVISION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0033089987     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X1999000300006     Document Type: Article

References (26)

1. Bravo R, Frank R, Blundell PA & Macdonald-Bravo H (1987). Cyclin/PCNA is the auxiliary protein DNA polymerasedelta. Nature, 326: 515-517.
2. Prelich G, Tan C-K, Kostura M, Mathews NB, So AG, Douney KM & Stillman B (1987). Functional identity of oroliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature, 326: 517-520.
3. Idikio HA (1996). Expression of proliferating cell nuclear antigen in node-negative human prostate cancer. Anticancer Research, 16: 2507-2611.
4. Ahlgren G, Lindholm K, Falkmer U & Abrahamsson P-A (1997). A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as prognosticating tool in patients with carcinoma of the prostate. Urology, 50: 379-384.
5. Tamboli P, Amin MB, Schultz DS, Linden MD & Kubus J (1996). Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia and prostatic carcinoma. Modern Pathology, 9: 1015-1019.
6. Lane DP (1992). p53 Guardian of the genome. Nature, 358: 15-16.
7. Isaacs WB, Carter BS & Ewing CM (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Research, 51: 4716-4720.
8. Levine AJ, Momand J & Finaly CA (1991). The p53 tumor suppressor gene. Nature, 351: 453-456.
9. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T & Isola J (1992). Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. Journal of the National Cancer Institute, 84: 883-887.
10. Navone N, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC & Conti CJ (1993). p53 protein accumulation and gene mutation in the progression of prostate carcinoma. Journal of the National Cancer Institute, 85: 1657-1669.
11. Shroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK & Pavone-Macaluzo M (1992). The TNM classification of prostate carcinoma Prostate, 4 (Suppl): 129-138.
12. Shi SR, Key ME & Kalra KL (1991). Antigen retrieval in formalin-fixed paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. Journal of Histochemistry and Cytochemistry, 39: 741-748.
13. Taylor CR & Cote RJ (1994). Immunomicroscopy: a diagnostic tool for the surgical pathologist. In: Major Problems in Pathology Series. Vol 19. 2nd edn. W.B. Saunders, Philadelphia.
14. Leonardi E, Girlando S, Seio G, Mauri FA, Perrone G, Sampini S, Dalla Palma P & Barbareschi M (1992). PCNA and Ki-67 expression in breast carcinoma: correlation with clinical and biological variables Journal of Clinical Pathology, 45: 416-419.
15. Ueda T, Aozaca K, Tsujimoto M, Ohsawa M, Uchida A, Aoki Y, Ono K & Matsumoto K (1989). Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer, 63: 1607-1611.
16. Raymond WA, Leong AS-Y, Bolt JW, Milios J & Jose JS (1988). Growth fractions in human prostatic carcinoma determined by Ki-67 immunostainmg. Journal of Pathology, 156: 161-167.
17. Galee MPW, Visser-DeJong E, ten Kate FJW, Schroeder FH & van der Kwast TH (1989). Monoclonal antibody Ki-67 defined growth fraction in benign prostate hyper-plasia and prostatic cancer. Journal of Urology, 142: 1342-1346.
18. Montironi R. Galluzzi CM, Scarpelli M & Diamanti L (1994). Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. Journal of Cellular Biochemistry, 19 (Suppl): 238-245.
19. Meyer JS, Sufrin G & Martin SA (1982). Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. Journal of Urology, 128: 1353-1356.
20. Nemoto R, Uchida K, Shimazui T, Hattori K, Koiso K & Harada M (1989). Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma. Journal of Urology, 141: 337-340.
21. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P & Mihatsch MJ (1996). Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. Journal of Pathology, 178: 437-441.
22. Momand J & Zambetti G (1997). Mdm-2: "Big Brother" of p53. Journal of Cellular Biochemistry, 64: 343-352.
23. Werness BA, Levine AJ & Howley PM (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248: 76-79.
24. Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt M-C, McLeod DG, Srivastava S & Moul JW (1997). Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer, 79: 952-962.
25. Taylor CR, Shi S-R & Cote RJ (1996). Antigen retrieval for immunohistochemistry. Status and need for greater standardization. Applied Immunohistochemistry, 4: 144-166.
26. Leong AS-Y, Milios J & Leong J (1996). Epitope retrieval with microwaves. Applied Immunohistochemistry, 4: 201-207.